Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2012

GSK, Canadian Center Launch Funds to Bolster Commercialization of Research

  • The Centre for Drug Research and Development (CDRD), its commercial arm, CDRD Ventures (CVI), and GlaxoSmithKline (GSK) in Canada are collaborating to provide financial resources and drug development expertise to Canadian research institutions. GSK will provide project-based funding to support the commercialization of health research.

    The first such vehicle is a “GSK-CDRD Innovation Fund” within CDRD to support certain early-stage projects to be conducted by CDRD and carried out in collaboration with academic investigators at CDRD's affiliated institutions and/or hospital-based research centers. A joint Innovation Committee comprising both GSK and CDRD representatives as well as external reviewers will select projects to be supported from this fund.

    The second fund is a joint venture with CVI that will invest in advancing projects further toward commercialization. Under this relationship, CVI will either conduct research itself or manage the projects. These studies will be partially funded by GSK.

    “These funds represent a novel continuum of funding resulting in a greater pool of resources being available to support health research projects at our various stages of development, whether they are very early projects in CDRD or more mature projects that have been advanced into CVI,” remarks Natalie Dakers, president and CEO of CDRD and CVI.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »